Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ETGlobeNewsWire • 06/29/21
Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer PatientsBenzinga • 06/29/21
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung CancerGlobeNewsWire • 06/29/21
Iovance's Lifileucel Shows Meaningful Increase in Response Time with Primary Anti-PD-1 Resistance in Melanoma TrialBenzinga • 06/07/21
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual MeetingGlobeNewsWire • 06/06/21
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual MeetingGlobeNewsWire • 06/04/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Iovance Biotherapeutics (IOVA) Investors With Losses and Persons Who May Assist Firm's Investigation Into Possible Securities Law Violations to Contact Its Attorneys NowPRNewsWire • 05/20/21
Ademi LLP Investigates Claims of Securities Fraud against Iovance Biotherapeutics, Inc.PRNewsWire • 05/20/21
Is the Options Market Predicting a Spike in Iovance Biotherapeutics (IOVA) Stock?Zacks Investment Research • 05/20/21
The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of InvestorsBusiness Wire • 05/20/21
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual MeetingGlobeNewsWire • 05/19/21
Additional Assay Data Holdup Delays Iovance's Lifileucel Filing Again, CEO Resigns; Shares PlungeBenzinga • 05/19/21
Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency AssaysGlobeNewsWire • 05/18/21
Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic MelanomaGlobeNewsWire • 05/12/21